Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
CORRESPONDENCE
Year : 2014  |  Volume : 10  |  Issue : 3  |  Page : 752-754

Autologous immune enhancement therapy in a case of gall bladder cancer stage IV after surgical resection and chemotherapy yielding a stable non-progressive disease


1 Shree Saibaba Heart Institute and Research Centre, Nashik, Maharashtra, India
2 The Mary-Yoshio Translational Hexagon, Nichi-In Centre for Regenerative Medicine, Chennai, Tamil Nadu
3 Biotherapy Institute of Japan, Tokyo, Japan
4 The Fujio-Eiji Academic Terrain, Nichi-In Centre for Regenerative Medicine, Chennai, Tamil Nadu, India
5 The Fujio-Eiji Academic Terrain, Nichi-In Centre for Regenerative Medicine; Hope Foundation (Trust), Chennai, Tamil Nadu, India
6 The Mary-Yoshio Translational Hexagon, Nichi-In Centre for Regenerative Medicine, Chennai, Tamil Nadu, India; Yamanashi University-School of Medicine, Chuo, Japan

Correspondence Address:
Dr. Samuel J K Abraham
The Mary-Yoshio Translational Hexagon, Nichi-In Centre for Regenerative Medicine, PB 1262, Nungambakkam, Chennai - 600 034, Tamil Nadu, India

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.136048

Rights and Permissions

Advanced gall bladder cancer generally has a poor prognosis and also shows decreased response to conventional therapies like chemotherapy and radiotherapy. Though surgical resection is the most common approach followed, the 1-year survival rate is only 10%. Herein, we report the outcome of administration of autologous natural killer cell and activated T lymphocyte-based autologous immune enhancement therapy (AIET) in a case of gall bladder cancer stage IV which was progressing in spite of surgical resection and several sittings of chemotherapy. There were no adverse reactions after AIET. After three infusions of AIET, an improvement of the quality of life and general condition which is sustaining for more than 6 months and a substantial decrease in the CA 19-9 marker levels from 2938.22 U/mL before AIET to 511 U/mL, 5 months after AIET, in our experience make us recommend AIET along with other conventional treatments in similar cases.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2519    
    Printed73    
    Emailed1    
    PDF Downloaded132    
    Comments [Add]    

Recommend this journal